TGFBR2 and breast cancer: Our data show that Smad4 expression in breast cancer is lower than in normal adjacent breast epithelial tissue and imply that impairment of TGF-β/Smad-signaling because of loss of TβRII or Smad4 might improve 5-year survival by possibly slowing down metastases.